Avet recalls tetracycline antibiotic capsules on low-potency fears

Antibiotic-resistant bacteria
Avet will pull its tetracycline capsules off U.S. shelves on low dissolution concerns. (Getty)

For patients taking generic antibiotics, adequate potency levels can mean the difference between a quick recovery and a trip to the hospital. But what happens if that potency isn't up to snuff? Manufacturer Avet Pharmaceuticals doesn't want to find out.

RELATED: Pfizer, Mylan say COVID-19 delays will postpone their Viatris merger

Avet has issued a voluntary nationwide recall of tetracycline antibiotic capsules marketed under the Heritage Pharmaceuticals brand because of low dissolution levels.

The recalled lots of 250- and 500-milligram capsules were distributed between August and March, the FDA said. So far, the drugmaker has not received any adverse event reports or complaints.

The FDA warned that low levels of dissolution in the body could limit the drug's ability to fight off serious infections like pneumonia, potentially leading to the progression of the infection or death.

RELATED: Amneal yanks ulcer drug off U.S. shelves on fears of carcinogen contamination

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.